These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33433138)

  • 1. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: The New Working Horse in Cardiovascular Pharmacology?
    Lemoine MD; Christ T
    J Cardiovasc Pharmacol; 2021 Mar; 77(3):265-266. PubMed ID: 33433138
    [No Abstract]   [Full Text] [Related]  

  • 2. The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.
    Ye L; Ni X; Zhao ZA; Lei W; Hu S
    J Cardiovasc Transl Res; 2018 Oct; 11(5):366-374. PubMed ID: 29845439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
    Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
    Del Álamo JC; Lemons D; Serrano R; Savchenko A; Cerignoli F; Bodmer R; Mercola M
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1717-27. PubMed ID: 26952934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.
    Shaheen N; Shiti A; Gepstein L
    Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.
    Lu HR; Whittaker R; Price JH; Vega R; Pfeiffer ER; Cerignoli F; Towart R; Gallacher DJ
    Toxicol Sci; 2015 Dec; 148(2):503-16. PubMed ID: 26358003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro uses of human pluripotent stem cell-derived cardiomyocytes.
    Matsa E; Denning C
    J Cardiovasc Transl Res; 2012 Oct; 5(5):581-92. PubMed ID: 22639342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
    Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced pluripotent stem cells in cardiovascular drug discovery.
    Mercola M; Colas A; Willems E
    Circ Res; 2013 Feb; 112(3):534-48. PubMed ID: 23371902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?
    Bruyneel AA; McKeithan WL; Feyen DA; Mercola M
    Curr Opin Pharmacol; 2018 Oct; 42():55-61. PubMed ID: 30081259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes.
    Bedada FB; Wheelwright M; Metzger JM
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1829-38. PubMed ID: 26578113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production.
    Thomas D; Cunningham NJ; Shenoy S; Wu JC
    Cardiovasc Res; 2022 Jan; 118(1):20-36. PubMed ID: 33757124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
    Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
    Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.
    Sallam K; Li Y; Sager PT; Houser SR; Wu JC
    Circ Res; 2015 Jun; 116(12):1989-2004. PubMed ID: 26044252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes.
    Zanella F; Lyon RC; Sheikh F
    Trends Cardiovasc Med; 2014 Jan; 24(1):32-44. PubMed ID: 24054750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling Cardiac Disease Mechanisms Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Progress, Promises and Challenges.
    Parrotta EI; Lucchino V; Scaramuzzino L; Scalise S; Cuda G
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
    Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
    Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.